申请人:Cubist Pharmaceuticals, Inc.
公开号:US20130289012A1
公开(公告)日:2013-10-31
β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
β-内酰胺酶抑制剂化合物(BLIs)已被披露,包括对A类、C类或D类β-内酰胺酶具有活性的化合物。还披露了BLIs的制造方法,以及这些化合物在制备药物组合物和抗菌应用中的用途。